Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Biogen's (BIIB) Big Moves Signal Future Sale
July 21, 2016 1:11 PM EDTBiogen (NASDAQ: BIIB) made a number of key changes Thursday and that has investors thinking a takeover could be in the company's future. The speculation has shares up over 7%.
First, Biogen announced that long-time CEO, George Scangos, is stepping down. Also, major... More
Biogen (BIIB) Announces 3 Major Changes to Get the Stock Moving Higher - BMO Capital
July 21, 2016 8:44 AM EDTBMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) noting 3 major change were announced this morning to get the stock moving higher:
1) departure of CEO, George Scangos,
2) major cost cutting initiatives that led to 2016 non-GAAP EPS guidance being raised to $19.70-20.00 from... More
Scangos Retirement May Be Precursor to Big M&A Plans at Biogen (BIIB) - Leerink
July 21, 2016 8:24 AM EDTLeerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) after the company reported earnings, announced a $5bn share buyback as well as the retirement of CEO George Scangos.
"We expect BIIBs stock to be modestly higher following these results, but... More
Biogen (BIIB) Approves $5B Stock Buyback Program
July 21, 2016 7:06 AM EDTBiogen (NASDAQ: BIIB) announced that its Board of Directors authorized a program to repurchase up to $5 billion of the Companys common stock. Biogen currently expects that purchases will be executed over the next three years. This share repurchase program is in addition to the... More
